Tìm theo
Bepridil
Các tên gọi khác (2) :
  • Bepadin
  • Bepridil
antihypertensive agents, anti arrhythmia agents, vasodilator agents, calcium channel blockers
Thuốc Gốc
Small Molecule
CAS: 64706-54-3
ATC: C08EA02
CTHH: C24H34N2O
PTK: 366.5396
A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
Phân tử khối
366.5396
Monoisotopic mass
366.26711372
InChI
InChI=1S/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3
InChI Key
InChIKey=UIEATEWHFDRYRU-UHFFFAOYSA-N
IUPAC Name
N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline
Traditional IUPAC Name
bepridil
SMILES
CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
Độ tan chảy
128
Độ hòa tan
Slightly soluble
logP
5.2
logS
-4.8
pKa (Strongest Basic)
9.16
PSA
15.71 Å2
Refractivity
115.12 m3·mol-1
Polarizability
43.5 Å3
Rotatable Bond Count
10
H Bond Acceptor Count
3
H Bond Donor Count
0
Physiological Charge
1
Number of Rings
3
Bioavailability
1
Ghose Filter
true
MDDR-Like Rule
true
Dược Lực Học : Bepridil is a calcium channel blocker that has well characterized anti-anginal properties and known but poorly characterized type 1 anti-arrhythmic and anti-hypertensive properties. It is not related chemically to other calcium channel blockers such as diltiazem hydrochloride, nifedipine and verapamil hydrochloride.
Cơ Chế Tác Dụng : A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). Bepridil has inhibitory effects on both the slow calcium (L-type) and fast sodium inward currents in myocardial and vascular smooth muscle, interferes with calcium binding to calmodulin, and blocks both voltage and receptor operated calcium channels. Bepridil inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. This has been demonstrated in isolated myocardial and vascular smooth muscle preparations in which both the slope of the calcium dose response curve and the maximum calcium-induced inotropic response were significantly reduced by bepridil. In cardiac myocytes in vitro, bepridil was shown to be tightly bound to actin. Bepridil regularly reduces heart rate and arterial pressure at rest and at a given level of exercise by dilating peripheral arterioles and reducing total peripheral resistance (afterload) against which the heart works.
Dược Động Học :
▧ Absorption :
Rapidly and completely absorbed after oral administration.
▧ Protein binding :
99%
▧ Metabolism :
Hepatic.
▧ Half Life :
24-50 hours
Độc Tính : There has been one experience with overdosage in which a patient inadvertently took a single dose of 1600 mg of bepridil. The patient was observed for 72 hours in intensive care, but no significant adverse experiences were noted.
Chỉ Định : For the treatment of hypertension, and chronic stable angina (classic effort-associated angina).
Tương Tác Thuốc :
  • Amprenavir Amprenavir may increase the effect and toxicity of bepridil.
  • Artemether Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Astemizole Increased risk of cardiotoxicity and arrhythmias
  • Atazanavir Atazanavir may increase the effect and toxicity of bepridil.
  • Cisapride Increased risk of cardiotoxicity and arrhythmias
  • Etravirine Bepridil (withdrawn from US. market), when used concomitantly with etravirine, may experience a decrease in serum concentration. If possible, it is recommended to monitor for decreased bepridil concentrations and therapeutic efficacy.
  • Fosamprenavir Amprenavir increases the effect and toxicity of bepridil
  • Gatifloxacin Increased risk of cardiotoxicity and arrhythmias
  • Grepafloxacin Increased risk of cardiotoxicity and arrhythmias
  • Levofloxacin Increased risk of cardiotoxicity and arrhythmias
  • Lumefantrine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Moxifloxacin Increased risk of cardiotoxicity and arrhythmias
  • Ritonavir Ritonavir increases the effect and toxicity of bepridil
  • Sparfloxacin Increased risk of cardiotoxicity and arrhythmias
  • Telavancin Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Terfenadine Increased risk of cardiotoxicity and arrhythmias
  • Tipranavir Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Bepridil. Concomitant therapy is contraindicated.
Liều Lượng & Cách Dùng : Tablet, film coated - Oral
Dữ Kiện Thương Mại
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Angopril
  • Công ty :
    Sản phẩm biệt dược : Cordium
  • Công ty :
    Sản phẩm biệt dược : Vascor
... loading
... loading